Celcuity Stock Rises Following Analyst Coverage Initiation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CELC?
Source: Fool
- Analyst Coverage Boost: Celcuity (CELC) shares surged nearly 4% following analyst Silvan Turkcan's initiation of coverage, indicating strong market optimism and reflecting investor confidence in the biotech sector.
- Price Target Set: Turkcan set a price target of $150 per share for Celcuity, nearly 20% above the company's latest closing price, which is considered optimistic among analysts and may attract more investor interest.
- Drug Potential Analysis: The report focuses on gedatolisib, an investigational drug targeting advanced breast cancer, with the FDA set to complete its review of the New Drug Application in less than two months, which could significantly enhance the company's value if approved.
- Increased Market Attention: With gedatolisib's promising market potential, Celcuity has become a focal point for biotech investors; despite its high stock price, the potential of its leading drug candidate could further elevate its market value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 121.030
Low
94.00
Averages
106.50
High
126.00
Current: 121.030
Low
94.00
Averages
106.50
High
126.00
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Celcuity's Drug Nears FDA Review Approval
- Analyst Coverage Initiated: Analyst Silvan Turkcan initiated coverage on Celcuity with a 'buy' rating and a price target of $150 per share, nearly 20% above the latest closing price, reflecting strong market confidence in the company.
- Clinical Candidate Outlook: Celcuity's leading drug candidate, gedatolisib, targets advanced breast cancer, with the FDA set to complete its review of the New Drug Application in less than two months, which could significantly boost the company's market value and attract more investor interest.
- Potential Market Impact: Gedatolisib is not only expected to treat breast cancer; the analyst noted its potential for approval in other indications, which would further enhance its market value and strengthen Celcuity's strategic position.
- Increased Investor Attention: With gedatolisib's high potential, Celcuity has become a focal point for biotech investors, and despite the high stock price, the potential of its leading drug candidate could further elevate its market value.
See More
Celcuity Stock Rises Following Analyst Coverage Initiation
- Analyst Coverage Boost: Celcuity (CELC) shares surged nearly 4% following analyst Silvan Turkcan's initiation of coverage, indicating strong market optimism and reflecting investor confidence in the biotech sector.
- Price Target Set: Turkcan set a price target of $150 per share for Celcuity, nearly 20% above the company's latest closing price, which is considered optimistic among analysts and may attract more investor interest.
- Drug Potential Analysis: The report focuses on gedatolisib, an investigational drug targeting advanced breast cancer, with the FDA set to complete its review of the New Drug Application in less than two months, which could significantly enhance the company's value if approved.
- Increased Market Attention: With gedatolisib's promising market potential, Celcuity has become a focal point for biotech investors; despite its high stock price, the potential of its leading drug candidate could further elevate its market value.
See More
Celcuity Reports Final 2025 Financial Results with Narrower Loss
- Financial Performance Surprise: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than the $32.3 million loss in 2024, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Increased R&D Spending: The company did not report any revenue but saw operating expenses rise to over $49 million in Q4, up from over $36 million in the same period of 2024, reflecting its ongoing commitment to research and development during this phase.
- Strong Cash Reserves: Celcuity's cash and cash equivalents totaled nearly $166 million at the end of the quarter, a substantial increase from $22.5 million at the end of 2024, providing a solid financial foundation to support its operations without revenue.
- Optimistic Clinical Trial Outlook: The company anticipates topline results from its phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, if positive, could significantly boost market confidence in its growth potential.
See More
Celcuity Reports Final 2025 Financial Results with Surprising Bottom-Line Upside
- Financial Performance Surprises: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than last year's $32.3 million, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Strong Cash Position: The company's cash and cash equivalents rose to nearly $166 million at the end of Q4 2025, up from $22.5 million at the end of 2024, providing a solid financial runway for its ongoing research and development efforts, which is crucial for pre-revenue biotechs.
- Promising R&D Developments: Celcuity anticipates topline results from a phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, regardless of the outcome, could lay the groundwork for future revenue opportunities.
- Positive Market Reaction: Following the earnings release, Celcuity's stock surged over 4%, reflecting investor optimism about the company's future potential, particularly given its robust cash foundation.
See More
Meta Platforms Faces Legal Setbacks, Stock Drops Over 6%
- Meta Legal Setbacks: Meta Platforms' stock dropped over 6% following losses in two major legal cases concerning child safety, raising concerns about Big Tech's role in social media safety and free speech protections, despite relatively minor financial penalties.
- AppLovin's Decline: AppLovin's shares fell nearly 8% due to reports of weakening e-commerce spending trends, with insufficient new client momentum to offset churn in Q1, highlighting potential challenges in maintaining growth.
- Brown-Forman's Surge: Shares of Brown-Forman rose over 14% after Bloomberg reported that French spirits company Pernod Ricard is considering a bid, indicating strong market interest in the company's future acquisition potential.
- Pony AI's Expansion Plans: Pony AI's stock fell 13% after announcing ambitious robotaxi expansion plans alongside its first quarterly profit, but an 18% revenue drop due to project timing raises concerns about margin pressures despite doubling robotaxi revenue.
See More
Memory Stocks Plummet, Adobe Downgraded
- Memory Stock Decline: Shares of memory chipmakers fell sharply following Google's unveiling of a new AI model, with Sandisk dropping nearly 4% and Micron Technology, Western Digital, and Seagate Technology each declining about 2%, indicating significant memory demand pressures in the industry.
- Mining Stocks Drop: Shares of gold and silver miners fell alongside declining precious metal prices, with First Majestic Silver shedding about 5% and both Coeur Mining and Hecla Mining losing nearly 4%, reflecting a bearish sentiment in the precious metals market.
- Adobe Downgrade: Adobe's stock dipped 1.4% after William Blair downgraded it from outperform to market perform, highlighting uncertainty regarding its position as an AI winner or loser, which may impact investor confidence.
- Navan's Strong Guidance: Travel tech firm Navan soared 18% after guiding for strong revenue in 2027, expecting full-year revenue between $866 million and $874 million, exceeding market expectations, showcasing its robust growth potential in the industry.
See More
Celcuity's Drug Nears FDA Review Approval
- Analyst Coverage Initiated: Analyst Silvan Turkcan initiated coverage on Celcuity with a 'buy' rating and a price target of $150 per share, nearly 20% above the latest closing price, reflecting strong market confidence in the company.
- Clinical Candidate Outlook: Celcuity's leading drug candidate, gedatolisib, targets advanced breast cancer, with the FDA set to complete its review of the New Drug Application in less than two months, which could significantly boost the company's market value and attract more investor interest.
- Potential Market Impact: Gedatolisib is not only expected to treat breast cancer; the analyst noted its potential for approval in other indications, which would further enhance its market value and strengthen Celcuity's strategic position.
- Increased Investor Attention: With gedatolisib's high potential, Celcuity has become a focal point for biotech investors, and despite the high stock price, the potential of its leading drug candidate could further elevate its market value.
See More
Celcuity Stock Rises Following Analyst Coverage Initiation
- Analyst Coverage Boost: Celcuity (CELC) shares surged nearly 4% following analyst Silvan Turkcan's initiation of coverage, indicating strong market optimism and reflecting investor confidence in the biotech sector.
- Price Target Set: Turkcan set a price target of $150 per share for Celcuity, nearly 20% above the company's latest closing price, which is considered optimistic among analysts and may attract more investor interest.
- Drug Potential Analysis: The report focuses on gedatolisib, an investigational drug targeting advanced breast cancer, with the FDA set to complete its review of the New Drug Application in less than two months, which could significantly enhance the company's value if approved.
- Increased Market Attention: With gedatolisib's promising market potential, Celcuity has become a focal point for biotech investors; despite its high stock price, the potential of its leading drug candidate could further elevate its market value.
See More
Celcuity Reports Final 2025 Financial Results with Narrower Loss
- Financial Performance Surprise: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than the $32.3 million loss in 2024, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Increased R&D Spending: The company did not report any revenue but saw operating expenses rise to over $49 million in Q4, up from over $36 million in the same period of 2024, reflecting its ongoing commitment to research and development during this phase.
- Strong Cash Reserves: Celcuity's cash and cash equivalents totaled nearly $166 million at the end of the quarter, a substantial increase from $22.5 million at the end of 2024, providing a solid financial foundation to support its operations without revenue.
- Optimistic Clinical Trial Outlook: The company anticipates topline results from its phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, if positive, could significantly boost market confidence in its growth potential.
See More
Celcuity Reports Final 2025 Financial Results with Surprising Bottom-Line Upside
- Financial Performance Surprises: Celcuity reported a net loss of $38.4 million ($0.73 per share) for Q4 2025, which, while deeper than last year's $32.3 million, was significantly better than analysts' expectations of a $1.05 loss per share, indicating effective cost management.
- Strong Cash Position: The company's cash and cash equivalents rose to nearly $166 million at the end of Q4 2025, up from $22.5 million at the end of 2024, providing a solid financial runway for its ongoing research and development efforts, which is crucial for pre-revenue biotechs.
- Promising R&D Developments: Celcuity anticipates topline results from a phase 3 clinical trial of gedatolisib for advanced breast cancer in Q2, which, regardless of the outcome, could lay the groundwork for future revenue opportunities.
- Positive Market Reaction: Following the earnings release, Celcuity's stock surged over 4%, reflecting investor optimism about the company's future potential, particularly given its robust cash foundation.
See More
Meta Platforms Faces Legal Setbacks, Stock Drops Over 6%
- Meta Legal Setbacks: Meta Platforms' stock dropped over 6% following losses in two major legal cases concerning child safety, raising concerns about Big Tech's role in social media safety and free speech protections, despite relatively minor financial penalties.
- AppLovin's Decline: AppLovin's shares fell nearly 8% due to reports of weakening e-commerce spending trends, with insufficient new client momentum to offset churn in Q1, highlighting potential challenges in maintaining growth.
- Brown-Forman's Surge: Shares of Brown-Forman rose over 14% after Bloomberg reported that French spirits company Pernod Ricard is considering a bid, indicating strong market interest in the company's future acquisition potential.
- Pony AI's Expansion Plans: Pony AI's stock fell 13% after announcing ambitious robotaxi expansion plans alongside its first quarterly profit, but an 18% revenue drop due to project timing raises concerns about margin pressures despite doubling robotaxi revenue.
See More
Memory Stocks Plummet, Adobe Downgraded
- Memory Stock Decline: Shares of memory chipmakers fell sharply following Google's unveiling of a new AI model, with Sandisk dropping nearly 4% and Micron Technology, Western Digital, and Seagate Technology each declining about 2%, indicating significant memory demand pressures in the industry.
- Mining Stocks Drop: Shares of gold and silver miners fell alongside declining precious metal prices, with First Majestic Silver shedding about 5% and both Coeur Mining and Hecla Mining losing nearly 4%, reflecting a bearish sentiment in the precious metals market.
- Adobe Downgrade: Adobe's stock dipped 1.4% after William Blair downgraded it from outperform to market perform, highlighting uncertainty regarding its position as an AI winner or loser, which may impact investor confidence.
- Navan's Strong Guidance: Travel tech firm Navan soared 18% after guiding for strong revenue in 2027, expecting full-year revenue between $866 million and $874 million, exceeding market expectations, showcasing its robust growth potential in the industry.
See More
